OpACIN-neo: Optimal Neo-adjuvant Combination Scheme of Ipilimumab and Nivolumab

Sponsor

The Netherlands Cancer Institute (Other)

Overall Status

Active, not recruiting

CT.gov ID

NCT02977052

Collaborator

Bristol-Myers Squibb (Industry)

186

Enrollment

Locations

Arms

103

Anticipated Duration (Months)

46.5

Patients Per Site

0.5

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

This is an open-label three-arm phase 2 trial (including a Simon stage 2 design) consisting of 90 stage III melanoma patients randomized 1:1:1 to receive either 2 courses 3 mg/kg ipilimumab + 1 mg/kg nivolumab every 3 weeks (Arm A), 2 courses 1 mg/kg ipilimumab + 3 mg/kg nivolumab every 3 weeks (Arm B), or 2 courses ipilimumab 3 mg/kg, directly followed by 2 courses nivolumab 3 mg/kg every 2 weeks (Arm C). All three treatment arms are applied prior to surgery at week 6, 30 patients per arm. Patients will be stratified according to treatment center. An interim analysis will be performed after 13 patients have been included in each arm, thus in total 39 patients have been included.

PRADO extension cohort The trial will enroll in total about 100-110 melanoma patients with macroscopic stage III disease (RECIST measurable disease); inclusion will stop when 50 patients have achieved a pCR or pnCR. All patients will be treated (after marker placement into the largest lymph node metastasis) with the winner combination identified in the first part of the OpACIN-neo study which is 2 courses ipilimumab 1mg/kg + nivolumab 3mg/kg, q3wks. After 6 weeks of treatment, the patients will undergo only surgical resection of the marked index lymph node. Thereafter subsequent surgery and adjuvant therapy will be performed according to the achieved pathologic response.

Condition or Disease	Intervention/Treatment	Phase
Malignant Melanoma Stage III	Drug: Ipilimumab Drug: Nivolumab Procedure: Surgery Procedure: Blood for PBMCs Procedure: Biopsies	Phase 2

Study Design

Study Type:

Interventional

Actual Enrollment :

186 participants

Allocation:

Non-Randomized

Intervention Model:

Single Group Assignment

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

Multicenter Phase 2 Study to Identify of the Optimal Neo-Adjuvant Combination Scheme of Ipilimumab and Nivolumab (OpACIN-neo)

Actual Study Start Date :

Nov 1, 2016

Actual Primary Completion Date :

Jan 3, 2020

Anticipated Study Completion Date :

Jun 1, 2025

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Arm A: 2 courses ipi 3 + nivo 1 Patients receive 2 courses standard combination of ipilimumab 3 mg/kg + nivolumab 1 mg/kg q3wk prior to surgery at week 6. Blood for PBMCs and biopsies will be taken for translation research.	Drug: Ipilimumab Drug: Nivolumab Procedure: Surgery Surgery will be done at 6 weeks Procedure: Blood for PBMCs Blood will be taken for translational research on PBMCs Procedure: Biopsies Biopsies will be taken during screening and at relapse.
Experimental: Arm B: 2 courses ipi 1 + nivo 3 Patients receive 2 courses ipilimumab 1 mg/kg + nivolumab 3 mg/kg q3wk prior to surgery at week 6. Blood for PBMCs and biopsies will be taken for translation research.	Drug: Ipilimumab Drug: Nivolumab Procedure: Surgery Surgery will be done at 6 weeks Procedure: Blood for PBMCs Blood will be taken for translational research on PBMCs Procedure: Biopsies Biopsies will be taken during screening and at relapse.
Experimental: Arm C: 2 courses ipi 3 + 2 courses nivo 3 Patients receive 2 courses of ipilimumab 3 mg/kg q3wks, directly followed (> 2 hours and < 24 hours) by 2 courses nivolumab 3 mg/kg every 2 weeks prior to surgery at week 6. Blood for PBMCs and biopsies will be taken for translation research.	Drug: Ipilimumab Drug: Nivolumab Procedure: Surgery Surgery will be done at 6 weeks Procedure: Blood for PBMCs Blood will be taken for translational research on PBMCs Procedure: Biopsies Biopsies will be taken during screening and at relapse.
Experimental: PRADO extension cohort Patients will be treated with 2 courses ipilimumab and nivolumab at the dose level defined as the winner dosing scheme from OpACIN-neo, which is the dosing schedule of arm B. Surgery and adjuvant therapy Patients achieving a pCR or pnCR will not undergo CLND and will not receive any adjuvant treatment. Structural follow-up will be perfomed every 12 weeks by CT, ultrasound of regional lymph nodes. Patients achieving a pPR will undergo CLND and start structural follow-up (including CT and physical examination) every 12 weeks thereafter without any adjuvant treatment. Patients achieving no response (pNR) will undergo CLND and start at week 12 with adjuvant nivolumab 480mg q4wks for 52 weeks + radiotherapy (according to patient's and physicians' decision). In patients that are BRAF V600E/K mutation positive, adjuvant BRAF+MEK	Drug: Ipilimumab Drug: Nivolumab Procedure: Surgery Surgery will be done at 6 weeks Procedure: Blood for PBMCs Blood will be taken for translational research on PBMCs Procedure: Biopsies Biopsies will be taken during screening and at relapse.

Outcome Measures

Primary Outcome Measures

Safety as measured by the frequency of grade 3/4 immune-related adverse events, using CTCAE 4.03 [During the first 12 weeks.]
Response rate according to RECIST 1.1 [At 6 weeks]
Pathological response according to central pathological revision, according to pathological response criteria [At 6 weeks]
Pathologic response rate according to central revision of the marked index lymph node [At 6 weeks, prior surgery]
RFS at 24 months in patients achieving pCR or pnCR in their marked index lymph node and did not undergo CLND. RFS will be calculated from date of resection of the marked lymph node. [24 months]
RFS at 24 months in patients with pNR and being subsequently treated with adjuvant nivolumab+optional radiotherapy (or dabrafenib/trametinib if BRAFV600E pos. and treatment is approved). RFS will be calculated from day of resection of marked lymph node. [24 months]

Secondary Outcome Measures

Recurrence Free Survival [3 years after treatment initiation]
Description of late adverse events using CTCAE 4.03 [Up to 3 years after treatment initiation until new treatment]
Description of associations of mutational load, RNA tumor signatures, and tumor educated platelet signatures with tumor immune infiltrates and response [At 6 weeks]
Response rate according to RECIST 1.1 at week 6 [At 6 weeks]
RFS at 2, 3 and 5 years [Up to 5 years after treatment]

Other Outcome Measures

EFS at 2, 3 and 5 years [Up to 5 years after treatment]
DMFS at 2, 3 and 5 years [Up to 5 years after treatment]
OS at 2, 3 and 5 years [Up to 5 years after treatment]
Grade 3/4 immune-related adverse event rate according to CTCAE v4.03 within the first 12 weeks [At 12 weeks]
• Surgical complication rates according to Clavien-Dindo surgical classification of only marked index lymph node resection vs. CLND [At 12 weeks]
• Description of late adverse event (up to 3 years after treatment initiation) according to CTCAE v4.03 [Up to 3 years after treatment]

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Adults at least 18 years of age
World Health Organization (WHO) Performance Status 0 or 1
Cytologically or histologically confirmed resectable stage III melanoma with one or more macroscopic lymph node metastases (measurable according to RECIST 1.1), that can be biopsied, and no history of in-transit metastases within the last 6 months
No other malignancies, except adequately treated and a cancer-related life-expectancy of more than 5 years
Patient willing to undergo triple tumor biopsies and extra blood withdrawal during screening and in case of relapse
No prior immunotherapy targeting CTLA-4, PD-1 or PD-L1
No immunosuppressive medications within 6 months prior study inclusion
Screening laboratory values must meet the following criteria: WBC ≥ 2.0x109/L, Neutrophils ≥1.5x109/L, Platelets ≥100 x109/L, Hemoglobin ≥5.5 mmol/L, Creatinine ≤1.5x ULN, AST ≤ 1.5 x ULN, ALT ≤ 1.5 x ULN, Bilirubin ≤1.5 X ULN
Normal LDH
Women of childbearing potential (WOCBP) must use appropriate method(s) of contra-ception. WOCBP should use an adequate method to avoid pregnancy for 23 weeks (30 days plus the time required for nivolumab to undergo five half-lives) after the last dose of investigational drug
Women of childbearing potential must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 24 hours prior to the start of ipilimumab + nivolumab
Men who are sexually active with WOCBP must use any contraceptive method with a failure rate of less than 1% per year. Men receiving nivolumab and who are sexually active with WOCBP will be instructed to adhere to contraception for a period of 31 weeks after the last dose of investigational product
Women who are not of childbearing potential (i.e., who are postmenopausal), or surgically sterile as well as azoospermic men do not require contraception
Patient is capable of understanding and complying with the protocol requirements and has signed the Informed Consent document.

Exclusion Criteria:

Distantly metastasized melanoma
History of in-transit metastases within the last 6 months
No measurable lesion according to RECIST 1.1
Subjects with any active autoimmune disease or a documented history of autoimmune disease, or history of syndrome that required systemic steroids or immunosuppressive medications, except for subjects with vitiligo or resolved childhood asthma/atopy
Prior CTLA-4 or PD-1/PD-L1 targeting immunotherapy
Radiotherapy prior or post-surgery
Patients will be excluded if they test positive for hepatitis B virus surface antigen (HBV sAg) or hepatitis C virus ribonucleic acid (HCV antibody), indicating acute or chronic infection
Patients will be excluded if they have known history of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS)
Allergies and Adverse Drug Reaction
History of allergy to study drug components
History of severe hypersensitivity reaction to any monoclonal antibody
Underlying medical conditions that, in the Investigator's opinion, will make the administration of study drug hazardous or obscure the interpretation of toxicity determination or adverse events;
Concurrent medical condition requiring the use of immunosuppressive medications, or immunosuppressive doses of systemic or absorbable topical corticosteroids;
Use of other investigational drugs before study drug administration 30 days and 5 half-times before study inclusion
Pregnant or nursing

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Melanoma Institute Australia	Sydney	New South Wales	Australia	2060
2	Medical University of Vienna	Vienna		Austria	1090
3	Netherlands Cancer Institute	Amsterdam	NH	Netherlands	1066CX
4	Karolinska Institutet	Stockholm		Sweden	S-171 76